Conference Coverage

ADPKD and Subclinical Metabolic Abnormalities

Austin—Patients with autosomal dominant polycystic kidney disease (ADPKD) experience high lifetime morbidity, related to both renal sequelae and to cardiovascular risk. Recent studies have identified abnormal regulation of pathways affecting cellular signaling, proliferation, and apoptosis in patients with ADPKD. Future targets for treatment may include modifying factors related to abnormal lipid metabolism, insulin insensitivity, early hypertension, as well as other ... Read More »

Female Sex Protective Mortality Related to AKI

Austin—Patients who experience acute kidney injury (AKI) are at increased risk for short- and long-term mortality. Results of previous studies have revealed a higher risk of mortality among males with AKI; female sex has been shown to be protective in both the development of AKI and the AKI-related mortality risk. The majority of those studies utilize univariate analyses, without consideration ... Read More »

ANNA 2018 National Symposium Highlights

The American Nephrology Nurses Association (ANNA) held its 2018 National Symposium in Las Vegas, Nevada, April 15-18, 2018. The meeting included posters and presentations on topics such as hemodialysis, chronic kidney disease, acute kidney disease, use of telemedicine in pediatric nephrology care, and treatment with direct-acting antiviral therapy for patients with hepatitis C on dialysis. Jami S. Brown, DHEA, RN, ... Read More »

2018 Award Recipients Honored at NKF Spring Clinical Meetings

Leading kidney disease researchers, clinicians, patient advocates, government officials, and corporate partners were honored at the National Kidney Foundation (NKF) 2018 Spring Clinical Meetings Glenn M, Chertow, MD, professor of medicine at Stanford University and chief of Stanford School of Medicine’s Division of Nephrology, received the foundation’s highest honor, the 2018 David M. Hume Award. The award honors a “distinguished ... Read More »

Patients May Only Partially Report Symptom Burden of Hemodialysis

Austin, Texas—Patients on maintenance dialysis experience substantial burden of symptoms that are associated with impaired quality of life. Symptom control is cited as a top research priority by patients, but results of previous studies suggest that providers may underestimate the burden on patients. Researchers at the University of North Carolina, Chapel Hill, led by Adeline Dorough, BS, conducted a qualitative ... Read More »

Tolvaptan Reduced Renal-Pain Associated Costs in ADPKD Patients

Austin, Texas—Autosomal dominant polycystic kidney disease (ADPKD) is a progressive genetic kidney disease characterized by enlargement of bilateral renal cysts leading to loss of renal function. The TEMPO 3:4 trial demonstrated the efficacy of tolvaptan, a selective vasopressin V2-receptor antagonist. TEMPO 3:4 was a randomized, placebo-controlled trial involving 1445 patients over 3 years. An analysis of prespecified end points showed ... Read More »

Uromodulin Associated with Reduced Risk for Graft Failure

Austin, Texas—Andrew Bostom, MD, of the Center for Primary Care and Prevention, Memorial Hospital of Rhode Island, Pawtucket, recently conducted an analysis of longitudinal follow-up data from a study of 91 recipients of kidney transplantation. The analysis was designed to examine the association between baseline serum uromodulin and the development of graft failure. Uromodulin is a kidney-derived glycoprotein and putative ... Read More »

Vascapa® Reduces Triglycerides in Patients with Reduced Kidney Function and Elevated hsCRP

Austin, Texas—Patients with kidney disease and elevated high-sensitivity C-reactive protein (hsCRP) are at increased risk for cardiovascular disease. Vascepa® (icosapent ethyl), a high-purity ethyl ester of the omega-3 fatty acid, eicosapentaenoic acid, is approved at 4 g per day as an adjunct to diet to reduce triglycerides in adults with triglyceride level ≥500 mg/dL. Krishnaswami Vijsyaraghavan, MD, and colleagues conducted ... Read More »

Patiromer Shown Safe and Effective in Three Clinical Trials in Patients with Hyperkalemia

Austin, Texas—Veltassa® (patiromer), a sodium free, nonbasorbed potassium binder, is approved for treatment of patients in the United States and the European Union with hyperkalemia. Matthew Weir, MD, and colleagues recently conducted an analysis to examine the consistency of lowering serum potassium in trials of patiromer for hyperkalemia. Results of the analysis were reported during a poster session at the ... Read More »

Canagliflozin Safe and Effective in Patients with Reduced and Preserved Kidney Function

Austin, Texas—Glucose lowering in patients with type 2 diabetes can be achieved with sodium glucose co-transporter 2 inhibitors; the agents may confer renal benefits but because the glycemic efficacy is dependent on glomerular filtration rate (GFR), they are not approved for use in people with significantly reduced kidney function. Researchers recently performed a prespecified analysis of CANVAS (Canagliflozin Cardiovascular Assessment ... Read More »